Cancer Patient Tissueoid with Self‐Homing Nano‐Targeting of Metabolic Inhibitor
Abstract The current paradigm of cancer medicine focuses on patient‐ and/or cancer‐specific treatments, which has led to continuous progress in the development of patient representatives (e.g., organoids) and cancer‐targeting carriers for drug screening. As breakthrough concepts, i) living cancer ti...
Enregistré dans:
Auteurs principaux: | Hyo‐Jin Yoon, Young Shin Chung, Yong Jae Lee, Seung Eun Yu, Sewoom Baek, Hye‐Seon Kim, Sang Wun Kim, Jung‐Yun Lee, Sunghoon Kim, Hak‐Joon Sung |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Wiley
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/e8e6201eb435440cbaab6765c1b052e1 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Nanosilica-supported liposome (protocells) as a drug vehicle for cancer therapy
par: Belwal VK, et autres
Publié: (2018) -
Doxorubicin-loaded cell-derived nanovesicles: an alternative targeted approach for anti-tumor therapy
par: Goh WJ, et autres
Publié: (2017) -
Exosomes: mediators of communication in eukaryotes
par: Lopez-Verrilli,María A, et autres
Publié: (2013) -
Curcumin derivative 1, 2-bis [(3E, 5E)-3, 5-bis [(2-chlorophenyl) methylene]-4-oxo-1-piperidyl] ethane-1, 2-dione (ST03) induces mitochondria mediated apoptosis in ovarian cancer cells and inhibits tumor progression in EAC mouse model
par: Jinsha Koroth, et autres
Publié: (2022) -
Toward the next-generation phyto-nanomedicines: cell-derived nanovesicles (CDNs) for natural product delivery
par: Chaoxiang Chen, et autres
Publié: (2022)